Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. (603168.SS)

Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. (603168.SS) — VMCI valuation read

Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. (603168.SS) carries a VMCI composite of 34/100, 16 points below the Healthcare sector median of 50. Among mid-cap names, that gap places 603168.SS in the bottom third on the five-pillar weighting (Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%).

The 603168.SS insider tape has been silent for the past 30 days on Form 4. Where executives neither buy nor sell, the bull and bear cases lean harder on filings cadence and the next earnings line.

**Investor frame.** Value reads 603168.SS trades at 24.0x earnings, 33% above the Healthcare median of 18.0x, which compresses or extends through the 11.0x EV/EBITDA versus a Healthcare 12.0x. Quality: ROIC of 14.0% sits 4.0pp above the Healthcare median (10.0%). Risk: net debt to EBITDA of -1.8x leaves covenant headroom, the line to track on Zhejiang Shapuaisi Pharmaceutical Co.,Ltd.'s next 10-Q.

603168.SS fell 0.6% over the trailing 7 days, with a -10.3% read on a 30-day basis.